Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC.ORMP · Entity 6311 | Director | June 05, 2025 | June 09, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ORAMED PHARMACEUTICALS INC.
Report date June 05, 2025 · Filed June 09, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 134,531 |
Ending reported balance
After 2025-06-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-06-05 · Grant · Acquired 30,000 · Balance 128,021 F1: Represents Restricted Stock Units ("RSUs") that will vest in equal portions of 10,000 as follows: January 1, 2026, January 1, 2027 and January 1, 2028. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Row 2 · 2025-06-05 · Grant · Acquired 6,510 · Balance 134,531 F2: Represents RSUs that will vest in equal installments as follows: on grant, July 1, 2025, October 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units ("RSUs") that will vest in equal portions of 10,000 as follows: January 1, 2026, January 1, 2027 and January 1, 2028. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.
F2: Represents RSUs that will vest in equal installments as follows: on grant, July 1, 2025, October 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2025 Filed Jun 9, 2025 20:07 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 6,510 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-25-052620 · ownership.xml · nonDerivative · entry 2 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,531 F2 · price: Represents RSUs that will vest in equal installments as follows: on grant, July 1, 2025, October 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:07 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-25-052620 · ownership.xml · nonDerivative · entry 1 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,021 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest in equal portions of 10,000 as follows: January 1, 2026, January 1, 2027 and January 1, 2028. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 21:37 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 9,325 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-001143 · doc4.xml · nonDerivative · entry 2 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,021 F2 · price: Represents Restricted Stock Units ("RSUs") that will vest in quarterly installments of approximately 2,331 on April 1, 2024, July 1, 2024, October 1, 2024 and January 1, 2025. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 21:37 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-001143 · doc4.xml · nonDerivative · entry 1 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,696 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest in 3 installments as follows: 10,000 shall vest on each of January 1, 2025, January 1, 2026 and January 1, 2027. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| April 17, 2023 Filed Apr 20, 2023 10:00 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-024942 · doc4.xml · nonDerivative · entry 1 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,696 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest in equal quarterly installments of 2,500 over a three year period starting May 1, 2023. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 20:30 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Exercise / conversionStock Option · Derivative | 20,000 | $0.00 Strike: $4.08 | $0.00 |
DisclosureSEC source: 0001209191-22-045207 · doc4.xml · derivative · entry 3 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2022-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vested as follows: 10,000 vested on each of January 1, 2013 and 2014. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 20:30 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Tax withholdingCommon Stock | 9,304 | $8.77 | $81,596.08 |
DisclosureSEC source: 0001209191-22-045207 · doc4.xml · nonDerivative · entry 2 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,696 F1 · shares: Represents a cashless exercise of outstanding stock options to purchase 20,000 shares of common stock. The reporting person received 10,696 shares of common stock and surrendered 9,304 shares of common stock underlying the stock option in payment of the exercise price. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 20:30 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Exercise / conversionCommon Stock | 20,000 | $4.08 | $81,600.00 |
DisclosureSEC source: 0001209191-22-045207 · doc4.xml · nonDerivative · entry 1 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 28, 2022 Filed Aug 2, 2022 00:00 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 12,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-043766 · doc4.xml · nonDerivative · entry 1 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest in 3 installments as follows: 4,000 shall vest on each of January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. F2 · balance_after: The reporting person previously reported and disclaimed beneficial ownership over 138,889 shares of common stock owned by a company wholly owned by a trust of which the reporting person was previously a trustee. The reporting person resigned as a trustee of such trust, effective February 3, 2022. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 01:52 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $13.89 | $0.00 |
DisclosureSEC source: 0001213900-22-000822 · ownership.xml · derivative · entry 3 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-01-03 F3 · derivative.exercise_date: The Stock Option will vest in 4 installments as follows: 2,500 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 01:52 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 6,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-22-000822 · ownership.xml · nonDerivative · entry 1 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · price: Represents Restricted Stock Units ("RSUs") that will vest in 4 installments as follows: 1,500 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:12 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | OtherCommon Stock | 78,125 | $3.68 | $287,500.00 |
DisclosureSEC source: 0001213900-21-012894 · ownership.xml · nonDerivative · entry 2 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Via trust Disclosed balance after: 0 F1 · kind: The reported securities were transferred to the Ledo Investment Holdings Limited trust (the "Trust"), which is administered by an independent trustee for the benefit of the reporting person and his immediate family members. The reporting person disclaims beneficial ownership of the securities held by the Trust except to the extent of his pecuniary interest therein. F1 · ownership.nature: The reported securities were transferred to the Ledo Investment Holdings Limited trust (the "Trust"), which is administered by an independent trustee for the benefit of the reporting person and his immediate family members. The reporting person disclaims beneficial ownership of the securities held by the Trust except to the extent of his pecuniary interest therein. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:12 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | OtherCommon Stock | 375,000 | $3.68 | $1,380,000.00 |
DisclosureSEC source: 0001213900-21-012894 · ownership.xml · nonDerivative · entry 1 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Via trust Disclosed balance after: 0 F1 · kind: The reported securities were transferred to the Ledo Investment Holdings Limited trust (the "Trust"), which is administered by an independent trustee for the benefit of the reporting person and his immediate family members. The reporting person disclaims beneficial ownership of the securities held by the Trust except to the extent of his pecuniary interest therein. F2 · shares: Due to an administrative rounding error following the Issuer's 1-to-12 reverse stock split, which occurred on January 10, 2013, the Form 4 filed for the reporting person on February 11, 2013 inadvertently understated the amount of shares beneficially owned by the reporting person following the transaction by 1 share, which error has been corrected on this Form 4. F1 · ownership.nature: The reported securities were transferred to the Ledo Investment Holdings Limited trust (the "Trust"), which is administered by an independent trustee for the benefit of the reporting person and his immediate family members. The reporting person disclaims beneficial ownership of the securities held by the Trust except to the extent of his pecuniary interest therein. Read SEC document |
| January 08, 2020 Filed Jan 14, 2020 21:08 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001213900-20-000993 · ownership.xml · derivative · entry 1 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-01-08 F1 · derivative.exercise_date: The Stock Option will vest in 3 installments as follows: 6,666 shall vest on December 31, 2020, and 6,667 shall vest on each of December 31, 2021 and December 31, 2022. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 21:17 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | PurchaseCommon Stock | 10,000 | $2.95 | $29,500.00 |
DisclosureSEC source: 0001213900-19-017770 · ownership.xml · nonDerivative · entry 2 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,999 Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 21:17 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | PurchaseCommon Stock | 15,000 | $2.90 | $43,500.00 |
DisclosureSEC source: 0001213900-19-017770 · ownership.xml · nonDerivative · entry 1 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,999 Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 17:31 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | PurchaseCommon Stock | 4,497 | $3.86 | $17,335.94 |
DisclosureSEC source: 0001213900-19-013085 · ownership.xml · nonDerivative · entry 4 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,999 Read SEC document |
| July 17, 2019 Filed Jul 18, 2019 17:31 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | PurchaseCommon Stock | 10,020 | $3.74 | $37,496.84 |
DisclosureSEC source: 0001213900-19-013085 · ownership.xml · nonDerivative · entry 3 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,502 Read SEC document |
| July 17, 2019 Filed Jul 18, 2019 17:31 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | PurchaseCommon Stock | 20,000 | $3.58 | $71,562.00 |
DisclosureSEC source: 0001213900-19-013085 · ownership.xml · nonDerivative · entry 2 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,482 Read SEC document |
| July 16, 2019 Filed Jul 18, 2019 17:31 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | PurchaseCommon Stock | 20,000 | $3.47 | $69,316.00 |
DisclosureSEC source: 0001213900-19-013085 · ownership.xml · nonDerivative · entry 1 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,482 Read SEC document |
| July 11, 2019 Filed Jul 15, 2019 23:02 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | PurchaseCommon Stock | 1,320 | $3.22 | $4,250.40 |
DisclosureSEC source: 0001213900-19-012780 · ownership.xml · nonDerivative · entry 1 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,482 Read SEC document |
| October 23, 2017 Filed Oct 25, 2017 20:35 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Exercise / conversionWarrant (right to buy) · Derivative | 6,373 | Not disclosed Strike: $6.00 | Not disclosed |
DisclosureSEC source: 0001213900-17-010951 · f4102317sank_oramedpharm.xml · derivative · entry 6 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,373 shares Expires 2018-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: The shares of common stock and warrants were granted to Mr. Sank as a finder's fee in connection with a 2012 private placement of the Issuer. Read SEC document |
| October 23, 2017 Filed Oct 25, 2017 20:35 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Exercise / conversionWarrant (right to buy) · Derivative | 5,631 | $1.18 Strike: $6.00 | $6,642.33 |
DisclosureSEC source: 0001213900-17-010951 · f4102317sank_oramedpharm.xml · derivative · entry 5 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,631 shares Expires 2017-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: The number of shares underlying such warrant and the applicable exercise price reflect a one-for-twelve reverse stock split effected by the issuer on January 22, 2013. F4 · price: The shares and warrants were purchased as "units" at a price per unit of $4.44 in connection with the Issuer's 2012 private placement. The consideration was allocated to the shares and warrants based on relative fair value. The value allocated to the warrants was estimated by using the Black Scholes option-pricing model. Read SEC document |
| October 23, 2017 Filed Oct 25, 2017 20:35 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Exercise / conversionCommon Stock | 6,373 | $6.00 | $38,238.00 |
DisclosureSEC source: 0001213900-17-010951 · f4102317sank_oramedpharm.xml · nonDerivative · entry 2 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 23, 2017 Filed Oct 25, 2017 20:35 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Exercise / conversionCommon Stock | 5,631 | $6.00 | $33,786.00 |
DisclosureSEC source: 0001213900-17-010951 · f4102317sank_oramedpharm.xml · nonDerivative · entry 1 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 20:22 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Exercise / conversionWarrant (right to buy) · Derivative | 11,262 | $1.18 Strike: $6.00 | $13,284.66 |
DisclosureSEC source: 0001213900-17-008889 · f4081517sank_oramedpharma.xml · derivative · entry 4 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,262 shares Expires 2017-08-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: The number of shares underlying such warrant and the applicable exercise price reflect a one-for-twelve reverse stock split effected by the issuer on January 22, 2013. F4 · price: The shares and warrants were purchased as "units" at a price per unit of $4.44 in connection with the Issuer's 2012 private placement. The consideration was allocated to the shares and warrants based on relative fair value. The value allocated to the warrants was estimated by using the Black Scholes option-pricing model. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 20:22 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Exercise / conversionCommon Stock | 11,262 | $6.00 | $67,572.00 |
DisclosureSEC source: 0001213900-17-008889 · f4081517sank_oramedpharma.xml · nonDerivative · entry 1 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 19:46 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 16,773 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001213900-17-007164 · f4063017sank_oramed.xml · derivative · entry 1 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,773 Underlying: Common Stock · 16,773 shares Expires 2027-06-30 F1 · derivative.exercise_date: The Stock Option will vest in 3 equal installments of 5,591 on each of December 31, 2017, December 31, 2018 and December 31, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.